
Commentary|Articles|March 16, 2015
Agents Targeted Against PSMA for Prostate Cancer
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.
Advertisement
Clinical Pearls
Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.
- As resistance to AR-targeted therapy develops, PSMA expression will increase in many patients. An agent targeted against PSMA could be added in at this time.
- PSMA-targeted therapy could also potentially be used in combination with AR-targeted therapy.
- Both AR- and PSMA-targeted therapies are being investigated in clinical trials and are already making an impact.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5
































